18520-63-3

Basic information

• Product Name: 1,4-Benzenedicarboxylic acid, mono(phenylmethyl) ester
• CAS NO: 18520-63-3
• Molecular Formula: C15H12O4
• Molecular Weight: 256.258
• Mol File: 18520-63-3.mol
• Article Data: 23

Chemical Properties

• CAS DataBase Reference: 1,4-Benzenedicarboxylic acid, mono(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Benzenedicarboxylic acid, mono(phenylmethyl) ester(18520-63-3)
• EPA Substance Registry System: 1,4-Benzenedicarboxylic acid, mono(phenylmethyl) ester(18520-63-3)

Safety Data

• Hazardous Substances Data: 18520-63-3(Hazardous Substances Data)

Usage

Molecular structure

A phthalic acid molecule with one of its carboxylic acid groups esterified with a phenylmethyl (benzyl) group

Physical state

Colorless, oily liquid

Odor

Slightly sweet

Uses

a. Plasticizer in vinyl flooring, adhesives, and synthetic resins
b. Solvent for dyes, perfumes, and insect repellents

Toxicity

Relatively low, but can cause skin and eye irritation

Health effects

Potential liver and kidney damage in high concentrations

Environmental impact

Potential environmental and health impacts, requiring cautious handling and appropriate safety measures

Upstream product

• 19851-61-7 p-dibenzyl benzenedicarboxylate 
• 78767-55-2 benzyl 4-formylbenzoate 
• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 100-20-9 terephthaloyl chloride 
• 100-39-0 benzyl bromide 
• 619-66-9 4-Carboxybenzaldehyde 
• 100-51-6 benzyl alcohol 
• 100-21-0 terephthalic acid 

Downstream Products

• 1357620-12-2 benzyl 4-(3-(dimethylamino)propylcarbamoyl)benzoate 
• 1357620-13-3 benzyl 4-(3-(diethylamino)propylcarbamoyl)benzoate 
• 1357620-14-4 benzyl 4-(3-morpholinopropylcarbamoyl)benzoate 
• 1357620-15-5 benzyl 4-(2-(dimethylamino)ethylcarbamoyl)benzoate 
• 1357620-16-6 benzyl 4-(2-morpholinoethylcarbamoyl)benzoate 
• 1155168-52-7 4-(3-(dimethylamino)propylcarbamoyl)benzoic acid 
• 1154357-88-6 4-(3-(diethylamino)propylcarbamoyl)benzoic acid 
• 1155162-37-0 4-(3-morpholinopropylcarbamoyl)benzoic acid 
• 1357620-17-7 N-(3-acetamido-5-((tert-butyldimethylsilyloxy)methyl)phenyl)-N'-(3-(dimethylamino)propyl) terephthalamide 
• 1357620-18-8 N-(3-acetamido-5-(hydroxymethyl)phenyl)-N'-(3-(dimethylamino)propyl)-terephthalamide 
• 1357620-22-4 N-(3-acetamidophenyl)-N'-(2-morpholinoethyl)terephthalamide 
• 1357620-23-5 N-(3-morpholinopropyl)-N'-phenylterephthalamide 
• 1365797-39-2 N-(4-benzyloxycarbonylbenzoyl)-N'-β-D-glucopyranosylurea 
• 1365797-41-6 N-(4-carboxybenzoyl)-N'-β-D-glucopyranosylurea 

Relevant articles and documents

Cyclic polybutylene terephthalate preparation

The invention specifically discloses a preparation method of novel cyclicpolybutylece terephthalate (PBT) dimer, wherein paraphthaloyl chloride and 1,4-butanediol are used as the raw materials for oriented synthesis of the cyclicpolybutylece terephthalate dimer through a protection and deprotectionstrategy, and the method is used for contrast analysis and detection of cyclicpolybutylece terephthalate dimer impurities in a PBT plastic. The chemical structural formula of the cyclicpolybutylece terephthalate dimer is described in the specification.

Mirror symmetry breaking in cubic phases and isotropic liquids driven by hydrogen bonding

Achiral supramolecular hydrogen bonded complexes between rod-like 4-(4-alkoxyphenylazo)pyridines and a taper shaped 4-substituted benzoic acid form achiral (Ia3d) and chiral “Im3m-type” bicontinuous cubic (I432) phases and a chiral isotropic liquid mesophase (Iso1[*]). The chiral phases, resulting from spontaneous mirror symmetry breaking, represent conglomerates of macroscopic chiral domains eventually leading to uniform chirality.

Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: From hit identification to an optimized lead

Growing evidence suggests that matrix metalloproteinases (MMP) are involved in thrombus dissolution; then, considering that new therapeutic strategies are required for controlling hemorrhage, we hypothesized that MMP inhibition may reduce bleeding by delaying fibrinolysis. Thus, we designed and synthesized a novel series of MMP inhibitors to identify potential candidates for acute treatment of bleeding. Structure-based and knowledge-based strategies were utilized to design this novel chemical series, α-spiropiperidine hydroxamates, of potent and soluble (>75 μg/mL) pan-MMP inhibitors. The initial hit, 12, was progressed to an optimal lead 19d. Racemic 19d showed a remarkable in vitro phenotypic response and outstanding in vivo efficacy; in fact, the mouse bleeding time at 1 mg/kg was 0.85 min compared to 29.28 min using saline. In addition, 19d displayed an optimal ADME and safety profile (e.g., no thrombus formation). Its corresponding enantiomers were separated, leading to the preclinical candidate 5 (described in Drug Annotations series, J. Med. Chem. 2015, 10.1021/jm501939z).